Sulfasalazine
- Generic Name
- Sulfasalazine
- Brand Names
- Azulfidine, Salazopyrin, Salazopyrin En-tabs
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14N4O5S
- CAS Number
- 599-79-1
- Unique Ingredient Identifier
- 3XC8GUZ6CB
- Background
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA). Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry ...
- Indication
In the US, sulfasalazine is indicated to treat mild to moderate ulcerative colitis and to prolong the remission period between acute attacks of ulcerative colitis. Sulfasalazine is also indicated as an adjunct therapy in severe ulcerative colitis.For the delayed-release tablet formulation, sulfasalazine is also indicated to treat rheumatoid arthritis in pedi...
- Associated Conditions
- Crohn's Disease (CD), Distal Ulcerative Colitis, Mild to Moderate Ulcerative Colitis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Proctitis, Rheumatoid Arthritis, Severe Ulcerative Colitis, Ulcerative Colitis in Remission
- Associated Therapies
- -
Sulfasalazine in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 50
- Registration Number
- NCT06134388
- Locations
- 🇪🇬
Tanta University Hospital, Tanta, El-Gharbia Governorate, Egypt
The Effect of Sulfasalazine on CRH Levels in Pregnant Women
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 50
- Registration Number
- NCT05703425
- Locations
- 🇺🇸
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Glutamate Inhibitors in Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 120
- Registration Number
- NCT05664464
- Locations
- 🇨🇭
University Hospital Zurich, Zürich, Zurich, Switzerland
Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 64
- Registration Number
- NCT05580861
- Locations
- 🇫🇷
CHU Nice, Nice, France
🇫🇷CHU Caen, Caen, France
🇫🇷CHU Henri Mondor, Créteil, France
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05445440
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 8
- Registration Number
- NCT04720183
- Locations
- 🇺🇸
Biotral Inc, Newark, New Jersey, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04528056
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04268394
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.